Free tool
FAERS Monitor: Diprolene
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 018741 or its brand name (Diprolene, Betamethasone Dipropionate). Reports on generic versions are filed under their own applications.
Reports
6,488
Serious
4,390
68% of reports
Hospitalization
1,999
Death reported
547
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- drug ineffective1,469
- off label use666
- macular degeneration533
- nausea527
- psoriasis508
- pruritus474
- pain472
- condition aggravated426
- fatigue410
- pain in extremity409
- rash404
- headache402
- dyspnoea360
- product use in unapproved indication350
- diarrhoea349
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 23 |
| 2005 | 42 |
| 2006 | 34 |
| 2007 | 38 |
| 2008 | 27 |
| 2009 | 38 |
| 2010 | 26 |
| 2011 | 52 |
| 2012 | 72 |
| 2013 | 54 |
| 2014 | 67 |
| 2015 | 122 |
| 2016 | 201 |
| 2017 | 230 |
| 2018 | 287 |
| 2019 | 389 |
| 2020 | 471 |
| 2021 | 779 |
| 2022 | 786 |
| 2023 | 791 |
| 2024 | 638 |
| 2025 | 747 |
| 2026 | 574 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,047,671 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| macular degenerationSignal | 533 | 151.4 | 139.3 | 75,968 |
| psoriasisSignal | 508 | 12.7 | 11.6 | 5,454 |
| product use in unapproved indicationSignal | 350 | 4.6 | 4.1 | 987 |
| condition aggravatedSignal | 426 | 4.5 | 4.1 | 1,191 |
| pain in extremitySignal | 409 | 4.5 | 4.1 | 1,126 |
| pruritusSignal | 474 | 4.0 | 3.7 | 1,083 |
| drug ineffectiveSignal | 1,469 | 3.6 | 3.5 | 2,960 |
| rashSignal | 404 | 3.0 | 2.7 | 550 |
| painSignal | 472 | 2.5 | 2.3 | 432 |
| off label useSignal | 666 | 2.5 | 2.3 | 604 |
| nauseaSignal | 527 | 2.2 | 2.0 | 339 |
| headacheSignal | 402 | 2.1 | 1.9 | 231 |
| dyspnoeaSignal | 360 | 2.1 | 1.9 | 201 |
| diarrhoea | 349 | 1.8 | 1.6 | 116 |
| fatigue | 410 | 1.7 | 1.6 | 124 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.